Enasidenib

Scientific Overview: IDH2 mutant inhibitor; FDA approved 2017 for R/R AML; differentiation therapy. First IDH2 inhibitor; established 2-HG oncometabolite targeting

Mechanism of Action: IDH2 Mutant Inhibitor

Purity: ≥99%  |  Molecular Formula: C19H17F3N8O

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.